Lyra Therapeutics Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 87

Employees

  • Stock Symbol
  • LYRA

Stock Symbol

  • Share Price
  • $0.21
  • (As of Friday Closing)

Lyra Therapeutics General Information

Description

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Contact Information

Formerly Known As
480 Biomedical, Arsenal Vascular, Arsenal Medical, Arsenal Vascular, Inc., Wmr Biomedical Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 480 Arsenal Way
  • Watertown, MA 02472
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 480 Arsenal Way
  • Watertown, MA 02472
  • United States
+1 (617)

Lyra Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lyra Therapeutics Stock Performance

As of 14-Feb-2025, Lyra Therapeutics’s stock price is $0.21. Its current market cap is $13.6M with 65.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.21 $0.21 $0.16 - $6.79 $13.6M 65.5M 1.69M -$1.49

Lyra Therapeutics Financials Summary

As of 30-Sep-2024, Lyra Therapeutics has a trailing 12-month revenue of $1.47M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (13,928) 179,171 (8,964) 277
Revenue 1,471 1,558 1,363 285
EBITDA (101,012) (66,842) (55,239) (42,614)
Net Income (97,612) (62,680) (55,278) (43,513)
Total Assets 78,756 142,600 109,968 54,867
Total Debt 35,324 26,881 4,177 1,453
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lyra Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lyra Therapeutics‘s full profile, request access.

Request a free trial

Lyra Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Lyra Therapeutics‘s full profile, request access.

Request a free trial

Lyra Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel
Drug Discovery
Watertown, MA
87 As of 2024

Gaithersburg, MD
 

Wuerzburg, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lyra Therapeutics Competitors (31)

One of Lyra Therapeutics’s 31 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
VeriNOS Pharmaceuticals Private Equity-Backed Wuerzburg, Germany
Nextera Venture Capital-Backed Oslo, Norway
Cyteir Therapeutics Formerly VC-backed Lexington, MA
MEI Pharma Corporation San Diego, CA
You’re viewing 5 of 31 competitors. Get the full list »

Lyra Therapeutics Patents

Lyra Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022234748-A1 Implantable corticosteroid matrix for sinus condition Pending 08-Mar-2021
GB-202313054-D0 Implantable corticosteroid matrix for sinus condition Pending 08-Mar-2021
GB-2618726-A Implantable corticosteroid matrix for sinus condition Pending 08-Mar-2021
CA-3210984-A1 Implantable corticosteroid matrix for sinus condition Pending 08-Mar-2021
US-20240041590-A1 Implantable corticosteroid matrix for sinus condition Pending 08-Mar-2021 A61F2/186
To view Lyra Therapeutics’s complete patent history, request access »

Lyra Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lyra Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lyra Therapeutics‘s full profile, request access.

Request a free trial

Lyra Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Lyra Therapeutics’s complete esg history, request access »

Lyra Therapeutics FAQs

  • When was Lyra Therapeutics founded?

    Lyra Therapeutics was founded in 2005.

  • Where is Lyra Therapeutics headquartered?

    Lyra Therapeutics is headquartered in Watertown, MA.

  • What is the size of Lyra Therapeutics?

    Lyra Therapeutics has 87 total employees.

  • What industry is Lyra Therapeutics in?

    Lyra Therapeutics’s primary industry is Drug Discovery.

  • Is Lyra Therapeutics a private or public company?

    Lyra Therapeutics is a Public company.

  • What is Lyra Therapeutics’s stock symbol?

    The ticker symbol for Lyra Therapeutics is LYRA.

  • What is the current stock price of Lyra Therapeutics?

    As of 14-Feb-2025 the stock price of Lyra Therapeutics is $0.21.

  • What is the current market cap of Lyra Therapeutics?

    The current market capitalization of Lyra Therapeutics is $13.6M.

  • What is Lyra Therapeutics’s current revenue?

    The trailing twelve month revenue for Lyra Therapeutics is $1.47M.

  • Who are Lyra Therapeutics’s competitors?

    NexImmune, VeriNOS Pharmaceuticals, Nextera, Cyteir Therapeutics, and MEI Pharma are some of the 31 competitors of Lyra Therapeutics.

  • What is Lyra Therapeutics’s annual earnings per share (EPS)?

    Lyra Therapeutics’s EPS for 12 months was -$1.49.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »